Resistance Bacterial clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not yet accepting patients
The trial, Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) (NCT02047981) demonstrated that biannual distribution of azithromycin to children 1-59 months old reduces child mortality. Targeting treatment to children 1-11 months old could reduce selection for resistance by limiting antibiotic distributions while maximizing the mortality benefit by targeting treatment to children at the highest mortality risk. Such a targeted intervention remains untested, however. The investigator's objective in this study is to determine the optimal age group to treat with biannual oral azithromycin distribution to reduce child mortality.